Previous close | 0.0745 |
Open | 0.0925 |
Bid | 0.1040 x N/A |
Ask | 0.1120 x N/A |
Day's range | 0.0925 - 0.0925 |
52-week range | 0.0655 - 0.7800 |
Volume | |
Avg. volume | 266 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 08 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q1 2024 Earnings Call Transcript May 11, 2024 NovaBay Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, welcome to the NovaBay Pharmaceuticals Financial Results Conference Call. At this time, all participants […]
EMERYVILLE, Calif., May 13, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces the introduction of an expanded line of Avenova® product bundles specifically designed to provide easy, affordable and effective solutions for individualized relief from dry eye symptoms. The new Avenova product bundles align with findings among optometrists surveyed in the Eyes on Eyecare 2024 Dry Eye Report of th
EMERYVILLE, Calif., May 09, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three months ended March 31, 2024 and provides a business update.